Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease

Am J Cardiol. 1998 Oct 1;82(7):898-901. doi: 10.1016/s0002-9149(98)00500-1.

Abstract

We studied 15 patients with chronic coronary artery disease (13 men aged 62 +/- 8 years) undergoing dobutamine (5 to 40 microg/kg/min) echocardiography at the end of two 15-day treatment periods with placebo and trimetazidine (20 mg 3 times daily) given in random order, according to a double-blind, crossover design. Results show that trimetazidine improves resting left ventricular function and reduces the severity of dobutamine-induced ischemic myocardial dysfunction.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Coronary Disease / complications
  • Coronary Disease / diagnostic imaging
  • Coronary Disease / physiopathology*
  • Cross-Over Studies
  • Dobutamine
  • Drug Administration Schedule
  • Echocardiography
  • Female
  • Humans
  • Male
  • Middle Aged
  • Trimetazidine / administration & dosage
  • Trimetazidine / therapeutic use*
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / therapeutic use*
  • Ventricular Dysfunction, Left / diagnostic imaging
  • Ventricular Dysfunction, Left / drug therapy*
  • Ventricular Dysfunction, Left / etiology

Substances

  • Vasodilator Agents
  • Dobutamine
  • Trimetazidine